Outcomes of patients in clinical trials with ST-segment elevation myocardial infarction among countries with different gross national incomes.

AIMS To evaluate whether there is an association between 30-day mortality in patients with ST-segment elevation myocardial infarction (STEMI) included in clinical trials and country gross national income (GNI). METHODS AND RESULTS A retrospective analysis of the databases of five randomized trials including 50 310 patients with STEMI (COBALT 7169, GIK-2 2931, HERO-2 17,089, ASSENT-2 17,005, and ASSENT-3 6116 patients) from 53 countries was performed. Countries were divided into three groups according to their GNI based on the World Bank data: low (less than 2900 US dollars), medium (between 2900 US dollars and 9000 US dollars), and high GNI (more than 9000 US dollars per capita). Baseline characteristics, in-hospital management variables, and 30-day outcomes were evaluated. A previously defined logistic regression model was used to adjust for differences in baseline characteristics and to predict mortality. The observed mortality was higher than the predicted mortality in the low (12.1 vs. 11.8%) and in the medium income groups (9.4 vs. 7.9%), whereas it was lower in the high income group (4.9 vs. 5.6%). CONCLUSION An inverse relationship between mortality and GNI was observed in STEMI clinical trials. Most of the variability in mortality can be explained by differences in baseline characteristics; however, after adjustment, lower income countries have higher mortality than the expected.

[1]  G. Montalescot,et al.  Évaluation des quatre premières années d'activité d'une unité de soins intensifs cardiologiques pour la prise en charge des syndromes coronaires aigus comparativement aux données régionales du registre GRACE (Global Registry of Acute Coronary Events) , 2005 .

[2]  R. Califf,et al.  International variation in the use of evidence-based medicines for acute coronary syndromes. , 2003, European heart journal.

[3]  P. Janský,et al.  International differences in in-hospital revascularization and outcomes following acute myocardial infarction: a multilevel analysis of patients in ASSENT-2. , 2003, European heart journal.

[4]  Sunil J Rao,et al.  Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis , 2003 .

[5]  H. White,et al.  Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERO-2 randomised trial , 2001, The Lancet.

[6]  Assent investigators.  Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction , 2001, The Lancet.

[7]  M. Flather,et al.  Potential impact of socioeconomic differences on clinical outcomes in international clinical trials. , 2001, American heart journal.

[8]  R. Califf,et al.  Variation in patient management and outcomes for acute coronary syndromes in Latin America and North America: results from the Platelet IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) trial. , 2001, American heart journal.

[9]  Frank E. Harrell,et al.  Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis , 2001 .

[10]  E. Antman,et al.  TIMI Risk Score for ST-Elevation Myocardial Infarction: A Convenient, Bedside, Clinical Score for Risk Assessment at Presentation: An Intravenous nPA for Treatment of Infarcting Myocardium Early II Trial Substudy , 2000, Circulation.

[11]  R. Califf,et al.  Canadian-American Differences in the Management of Acute Coronary Syndromes in the GUSTO IIb Trial: One-Year Follow-Up of Patients Without ST-Segment Elevation , 2000, Circulation.

[12]  M. Cohen,et al.  Inter-regional differences and outcome in unstable angina; analysis of the international ESSENCE trial. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-wave Coronary Events. , 2000, European heart journal.

[13]  J. O'shea,et al.  Inter-regional differences in acute coronary syndrome trials. , 2000, European heart journal.

[14]  F. Werf.  Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial , 1999, The Lancet.

[15]  Paul D. Allison,et al.  Logistic Regression Using the SAS System : Theory and Application , 1999 .

[16]  L. Piegas,et al.  Metabolic Modulation of Acute Myocardial Infarction The ECLA Glucose-Insulin-Potassium Pilot Trial , 1998 .

[17]  F. Werf.  A Comparison of Continuous Infusion of Alteplase with Double-Bolus Administration for Acute Myocardial Infarction , 1998 .

[18]  S. Yusuf,et al.  Variations between countries in invasive cardiac procedures and outcomes in patients with suspected unstable angina or myocardial infarction without initial ST elevation , 1998, The Lancet.

[19]  K. Lee,et al.  Coronary revascularization surgery after myocardial infarction: impact of bypass surgery on survival after thrombolysis. GUSTO Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. , 1997, Journal of the American College of Cardiology.

[20]  R. Califf,et al.  Difference in countries' use of resources and clinical outcome for patients with cardiogenic shock after myocardial infarction: results from the GUSTO trial , 1997, The Lancet.

[21]  Eric Boersma,et al.  Early thrombolytic treatment in acute myocardial infarction: reappraisal of the golden hour , 1996, The Lancet.

[22]  R. Califf,et al.  Variations in Patient Management and Outcomes for Acute Myocardial Infarction in the United States and Other Countries: Results From the GUSTO Trial , 1995 .

[23]  K. Lee,et al.  Variations in patient management and outcomes for acute myocardial infarction in the United States and other countries. Results from the GUSTO trial. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. , 1995, JAMA.

[24]  J Col,et al.  Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction. Results from an international trial of 41,021 patients. GUSTO-I Investigators. , 1995, Circulation.

[25]  G. Montalescot,et al.  [Management of acute coronary syndromes in a new French coronary intensive care unit. The first four years of activity in the GRACE registry (Global Registry of Acute Coronary Events)]. , 2005, Annales de cardiologie et d'angeiologie.

[26]  R. Diaz,et al.  International differences in patients, care and outcomes associated with acute myocardial infarction (AMI): the HERO-2 trial , 2003 .

[27]  R. Diaz,et al.  International differences in patients, care, and outcomes associated with acute myocardial infarction: the hero-2 trial , 2002 .

[28]  S. Windecker,et al.  Interventional cardiology in Europe 1994. Working Group Coronary Circulation of the European Society of Cardiology. , 1998, European heart journal.

[29]  F. Verheugt.  A comparison of continuous infusion of alteplase with double-bolus administration for acute myocardial infarction. , 1997, The New England journal of medicine.

[30]  Frans Van de Werf,et al.  An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. , 1993, The New England journal of medicine.